Aurora-A inhibitor, MLN8237 as a single agent, was ineffective in prolonging patient survival, so a strategy of combined inhibition of Aurora-A and Haspin may cooperatively regress the viability of breast cancer cells in vitro and in vivo.432 Moreover, IMMU-132, an antibody conjugate drug, and PARP inhibitors could significantly inhibit breast cancer cell growth and were well tolerated regardless of BRCA1/2 status. The gene discussed is PARP1; the disease is breast cancer.